Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The COVID-19 outbreak on the Diamond Princess has given researchers the rare opportunity to study the virus in a highly controlled population, in which almost everyone was tested. Plus: families face heartbreak as non-coronavirus clinical trials are put on hold, and the healing ozone layer is getting the jet stream back on track in the Southern Hemisphere.
Scientists are rushing to launch clinical trials of experimental vaccines and treatments for the coronavirus — while clinical trials of therapies for cancer and other illnesses are being put on hold. Neena Nizar and her family were poised to harvest the fruit of a decade of hard work and sacrifice: a clinical trial of an experimental treatment for her two sons’ rare and painful genetic disorder. Then came COVID-19. “I feel like we were chugging along on a train and then somebody dropped a huge boulder on it,” says Nizar.
The healing ozone layer above Antarctica is shifting wind patterns around the globe — most notably, pausing the movement toward the pole of the summertime jet stream in the Southern Hemisphere. Satellite observations and climate simulations reveal that the jet stream shifted from about 49° S to 51° S between 1980 and 2000. After 2000, when the ozone layer began to recover as a result of the Montreal Protocol that effectively banned ozone-killing chemicals, the change has halted.
• The COVID-19 outbreak on the cruise ship Diamond Princess has given researchers the rare opportunity to study the virus in a highly controlled population. Almost all of the 3,711 passengers and crew on the cruise ship were tested, some of them more than once. Some 700 people were infected, with a substantial number — 18% — showing no symptoms (the passengers included a large number of elderly people, who are most likely to develop severe disease if infected, so the share of asymptomatic people in the general population is probably higher). In a separate preprint study that has not yet been peer reviewed, taking into account data from the ship and from China, researchers estimate a case fatality rate of around 1.1% — much lower than the 3.8% estimated by the World Health Organization. (Nature | 5 min read)
• Some epidemiologists and public-health researchers are watching with horror as the United States fumbles the COVID-19 outbreak within its borders. A lack of preparation, a shortage of equipment where it’s needed and a shortfall in testing mean that the country might “end up with the worst outbreak in the industrialized world”, says epidemiologist Seth Berkley, who heads Gavi, the Vaccine Alliance. The Atlantic takes a scathing look at what it will take for the country to overcome the pandemic — and thrive afterwards. (The Atlantic | 22 min read)
After being disappointed with drug companies’ achievements after the SARS and MERS outbreaks, biologist Stephen Burley considers how to avoid the same mistakes with COVID-19. (Nature | 4 min read)
The Exclusion Zone around the wreck of the Chernobyl power plant, in present-day Ukraine, represents a glimpse of the past of civilization after its demise, the “final resting place of the future”. This has made the site of the 1986 nuclear accident into a morbidly fascinating tourist destination. “Immediately you are struck by the strange beauty of the place, the unchecked exuberance of nature finally set free of its crowning achievement, its problem child,” writes author Mark O’Connell.
A few modest adjustments to the planning and delivery of talks can help scientists to share ideas with their peers more effectively, say geographer Scott St. George and Nature climate-science editor Michael White. (Nature)
Invite me to your virtual dance party (just kidding, I’ll be combing through Met Office records) — or send me any feedback on this newsletter — at briefing@nature.com.
Flora Graham, senior editor, Nature Briefing
With contributions by Smriti Mallapaty and Davide Castelvecchi